Stock Update (NYSE:BMY): U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery

Bristol-Myers Squibb Company (NYSE:BMY) [Business Wire] – Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (
Read more on this.

Bristol-Myers Squibb Company (BMY), with a current value of $89.11B, started the session at $54.15.
 
Looking at the stock, its one day range is $53.88 to $54.44 and has traded between $38.26 and $57.49 over the past year.
 
BMY shares are currently priced at 30.44x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 7.91x earnings multiple for the same period.
 
And for income investors, the company pays shareholders $1.44 per share annually in dividends, yielding 2.60%.
 
According to a consensus of 14 analysts, the earnings estimate of $0.45 per share would be $0.04 better than the year-ago quarter and a $0.00 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $1.78 is a $0.04 setback when compared to the previous year’s annual results.
 
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $3.99 Billion. If realized, that would be a 4.18% increase over the year-ago quarter.
 
In terms of ratings, Barclays upgraded BMY from Equal Weight to Overweight (Jan 10, 2014). Previously, Jefferies downgraded BMY from Buy to Hold.
 
The average price target for BMY shares is $55.06, which is 1.68% above where the stock opened this morning.
 
Summary (NYSE:BMY) :  Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
 
Tag Helper ~ Stock Code: BMY | Common Company name: Bristol-Myers Squibb | Full Company name: Bristol-Myers Squibb Company (NYSE:BMY) .

More on this topic (What's this?)
BMY
Read more on Bristol-Myers Squibb Company at Wikinvest

Sharing the News


facebooktwittergoogle_plusredditlinkedinmail

Follow us for the Latest news


facebooktwittergoogle_pluslinkedinrss

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

Related Articles


Comments are closed.